Pembrolizumab and Olaparib for People With Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy
https://www.facingourrisk.org/research-clinical-trials/study/127/pembrolizumab-and-olaparib-for-metastatic-pancreatic-cancer-with-homologous-recombination-deficiency-or-exceptional-response-to-platinum-chemotherapy
Clinicaltrials.gov identifier:
NCT04666740 (https://clinicaltrials.gov/show/NCT04666740)
Treatment study for people diagnosed with metastatic pancreatic cancer with Homologous Recombination Deficiency, or whose disease has responded well to first-line or second-line platinum therapy
About the Study
NOTE: This study is no longer recruiting people.
This is a study for people diagnosed with metastatic pancreatic cancer with Homologous Recombination Deficiency, or whose disease has responded well to first-line or second-line platinum therapy. The goal of this study is to look at whether combining the immunotherapy drug, pembrolizumab and the PARP inhibitor, olaparib is a more effective treatment for this cancer than taking olaparib alone.
This Study is Open To:
NOTE: This study is no longer recruiting people.
This Study is Not Open To:
NOTE: This study is no longer recruiting people.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.